$PLX
Protalix BioTherapeutics, Inc. Stock $plx

$plx Overview Financials Valuation SEC Filings Company Website

2015 Q4 Form 10-Q Financial Statement

#000114420415063825 Filed on November 09, 2015

Income Statement

Concept	2015 Q4	2015 Q3	2014 Q4
Revenue	$0.00	$1.336M	-$10.25M
YoY Change	-100.0%	-44.24%	-1.35%
Cost Of Revenue	$0.00	$223.0K	-$6.850M
YoY Change	-100.0%	-87.6%	76.55%
Gross Profit	$0.00	$1.113M	-$3.410M
YoY Change	-100.0%	-41.7%	-47.7%
Gross Profit Margin		83.31%
Selling, General & Admin	$1.290M	$2.163M	$1.940M
YoY Change	-33.51%	7.5%	-2.51%
% of Gross Profit		194.34%
Research & Development	$7.700M	$5.068M	$4.070M
YoY Change	89.19%	-37.06%
% of Gross Profit		455.35%
Depreciation & Amortization	$560.0K	$590.0K	$720.0K
YoY Change	-22.22%	-25.32%	-15.29%
% of Gross Profit		53.01%
Operating Expenses	$7.700M	$7.231M	$7.030M
YoY Change	9.53%	-28.15%	-33.55%
Operating Profit	-$7.700M	-$5.002M	-$10.44M
YoY Change	-26.25%	-19.43%	-38.95%
Interest Expense	-$870.0K	-$1.010M	-$1.390M
YoY Change	-37.41%	-43.89%	87.84%
% of Operating Profit
Other Income/Expense, Net		-$1.013M
YoY Change		-43.78%
Pretax Income	-$8.570M	-$6.020M	-$11.82M
YoY Change	-27.5%	-24.84%	-33.71%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	$72.90M	-$3.820M	-$8.470M
YoY Change	-960.68%	-52.31%	-22.22%
Net Earnings / Revenue		-285.93%
Basic Earnings Per Share
Diluted Earnings Per Share	$7.21	-$0.40	-$0.89
COMMON SHARES
Basic Shares Outstanding	99.80M shares	94.15M shares	93.67M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q4	2015 Q3	2014 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$76.40M	$34.20M	$54.80M
YoY Change	39.42%	-43.28%	-36.57%
Cash & Equivalents	$76.37M	$34.25M	$54.77M
Short-Term Investments
Other Short-Term Assets	$1.667M	$2.716M	$2.202M
YoY Change	-24.3%	29.33%	51.13%
Inventory	$5.767M	$6.339M	$3.451M
Prepaid Expenses	$408.0K		$369.0K
Receivables	$0.00	$4.573M	$1.884M
Other Receivables		$0.00
Total Short-Term Assets	$85.88M	$47.88M	$65.52M
YoY Change	31.08%	-32.77%	-33.08%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.744M	$9.957M	$11.28M
YoY Change	-13.63%	-15.95%	-17.72%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.600M	$1.700M	$1.600M
YoY Change	0.0%	0.0%	-5.88%
Total Long-Term Assets	$11.37M	$11.62M	$12.84M
YoY Change	-11.41%	-14.51%	-16.8%
TOTAL ASSETS
Total Short-Term Assets	$85.88M	$47.88M	$65.52M
Total Long-Term Assets	$11.37M	$11.62M	$12.84M
Total Assets	$97.25M	$59.49M	$78.36M
YoY Change	24.12%	-29.84%	-30.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.534M	$4.100M	$6.802M
YoY Change	-18.64%	13.89%	28.34%
Accrued Expenses	$1.571M		$3.113M
YoY Change	-49.53%		74.4%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$11.24M	$22.85M	$64.35M
YoY Change	-82.54%	-6.28%	141.06%
LONG-TERM LIABILITIES
Long-Term Debt	$72.10M	$67.80M	$912.0K
YoY Change	7805.7%		-61.54%
Other Long-Term Liabilities	$3.000M	$37.40M	$2.300M
YoY Change	30.43%	-8.11%	-95.05%
Total Long-Term Liabilities	$75.15M	$105.2M	$69.60M
YoY Change	7.96%	-2.73%	-38.72%
TOTAL LIABILITIES
Total Short-Term Liabilities	$11.24M	$22.85M	$64.35M
Total Long-Term Liabilities	$75.15M	$105.2M	$69.60M
Total Liabilities	$86.38M	$128.0M	$134.0M
YoY Change	-35.52%	-3.39%	-4.51%
SHAREHOLDERS EQUITY
Retained Earnings	-$183.3M		-$241.3M
YoY Change	-24.05%		14.17%
Common Stock	$194.2M		$185.7M
YoY Change	4.54%		0.7%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$10.87M	-$68.51M	-$55.60M
YoY Change
Total Liabilities & Shareholders Equity	$97.25M	$59.49M	$78.36M
YoY Change	24.12%	-29.84%	-30.86%

Cashflow Statement

Concept	2015 Q4	2015 Q3	2014 Q4
OPERATING ACTIVITIES
Net Income	$72.90M	-$3.820M	-$8.470M
YoY Change	-960.68%	-52.31%	-22.22%
Depreciation, Depletion And Amortization	$560.0K	$590.0K	$720.0K
YoY Change	-22.22%	-25.32%	-15.29%
Cash From Operating Activities	-$3.850M	-$8.660M	-$4.870M
YoY Change	-20.94%	-9.32%	2.74%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$130.0K	$170.0K
YoY Change	-100.0%	-48.0%	-22.73%
Acquisitions
YoY Change
Other Investing Activities	$39.91M	-$40.00K	$0.00
YoY Change		33.33%	-100.0%
Cash From Investing Activities	$39.91M	-$170.0K	-$170.0K
YoY Change	-23576.47%	-34.62%	-37.04%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	6.110M	0.000	10.00K
YoY Change	61000.0%	-100.0%	-114.29%
NET CHANGE
Cash From Operating Activities	-3.850M	-8.660M	-4.870M
Cash From Investing Activities	39.91M	-170.0K	-170.0K
Cash From Financing Activities	6.110M	0.000	10.00K
Net Change In Cash	42.17M	-8.830M	-5.030M
YoY Change	-938.37%	-9.9%	-0.98%
FREE CASH FLOW
Cash From Operating Activities	-$3.850M	-$8.660M	-$4.870M
Capital Expenditures	$0.00	$130.0K	$170.0K
Free Cash Flow	-$3.850M	-$8.790M	-$5.040M
YoY Change	-23.61%	-10.31%	1.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	617000	USD
CY2015Q3	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1569000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	6667000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	47876000	USD
CY2014Q4	us-gaap	Defined Benefit Plan Assets For Plan Benefits Noncurrent DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent	1555000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9957000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11282000	USD
CY2015Q3	us-gaap	Deferred Costs DeferredCosts	90000	USD
CY2014Q4	us-gaap	Deferred Costs DeferredCosts	113000	USD
CY2015Q3	us-gaap	Assets Assets	59492000	USD
CY2014Q4	us-gaap	Assets Assets	78470000	USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2015Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	4057000	USD
CY2015Q3	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	11946000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	65520000	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-24407000	USD
CY2014Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	3951000	USD
CY2014Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	15496000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6763000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26210000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	37232000	USD
CY2014Q4	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2253000	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	107861000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-55601000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	2202000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-21474000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	683000	USD
	us-gaap	Depreciation Depreciation	2418000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-869000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	149000	USD
	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	25000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	332000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-6172000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	578000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1127000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1736000	USD
CY2015Q3	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6850000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	22853000	USD
CY2015Q3	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67774000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34248000	USD
CY2014Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	67464000	USD
CY2015Q3	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	35127000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	912000	USD
CY2015Q3	us-gaap	Pension And Other Postretirement And Postemployment Benefit Plans Liabilities Noncurrent PensionAndOtherPostretirementAndPostemploymentBenefitPlansLiabilitiesNoncurrent	2249000	USD
CY2015Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	105150000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	128003000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	134071000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54767000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	-68511000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	59492000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	78470000	USD
CY2015Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4573000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1884000	USD
CY2015Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2716000	USD
CY2015Q3	us-gaap	Inventory Net InventoryNet	6339000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-14863000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1419000	USD
	us-gaap	Depreciation Depreciation	1811000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-102000	USD
	us-gaap	Pension And Other Postretirement Benefit Expense PensionAndOtherPostretirementBenefitExpense	16000	USD
	plx	Gain Loss On Amounts Funded In Respect Of Employee Rights Upon Retirement GainLossOnAmountsFundedInRespectOfEmployeeRightsUponRetirement	-28000	USD
	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	333000	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-2018000	USD
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3187000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-328000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4396000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-20427000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	460000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	93000	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	122000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-516000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-832000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	534000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	43000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	534000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	43000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-110000	USD
	us-gaap	Effect Of Exchange Rate On Cash And Cash Equivalents EffectOfExchangeRateOnCashAndCashEquivalents	-885000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-20519000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	86398000	USD
	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	146000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3105000	USD
	us-gaap	Interest Paid Net InterestPaidNet	3079000	USD
	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash		USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	56000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-26946000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	161000	USD
	plx	Share Based Compensation Restricted Stock Awards Net Of Forfeitures ShareBasedCompensationRestrictedStockAwardsNetOfForfeitures	522000	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	43000	USD
CY2014Q3	us-gaap	Stockholders Equity StockholdersEquity	-47694000	USD
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	947000	USD
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	2501	shares
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-26081000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	60317000	USD
	plx	Increase In Liabilities For Property Plant And Equipment IncreaseInLiabilitiesForPropertyPlantAndEquipment	122000	USD
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	534000	USD
CY2014Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
	plx	Revenues Other Than Company Share In Collaboration Agreement RevenuesOtherThanCompanyShareInCollaborationAgreement	12475000	USD
	plx	Revenues Other Than Company Share In Collaboration Agreement RevenuesOtherThanCompanyShareInCollaborationAgreement	11517000	USD
	plx	Company Share In Collaboration Agreement CompanyShareInCollaborationAgreement	3084000	USD
	plx	Company Share In Collaboration Agreement CompanyShareInCollaborationAgreement	2259000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	6785000	USD
	us-gaap	Cost Of Revenue CostOfRevenue	7476000	USD
	us-gaap	Gross Profit GrossProfit	8774000	USD
	us-gaap	Gross Profit GrossProfit	6300000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	18493000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	23280000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	3856000	USD
	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	6146000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	14637000	USD
	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	17134000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	6259000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	7289000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-12122000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18123000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	2805000	USD
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	3490000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	64000	USD
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	139000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2741000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3351000	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93599414	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92828851	shares
CY2014Q3	us-gaap	Gross Profit GrossProfit	1909000	USD
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5260000	USD
CY2014Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	8052000	USD
CY2015Q3	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	1207000	USD
CY2014Q3	plx	Grants And Reimbursements Received Or Receivable GrantsAndReimbursementsReceivedOrReceivable	1947000	USD
CY2015Q3	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	4053000	USD
CY2014Q3	plx	Research Development And Engineering Expense Net ResearchDevelopmentAndEngineeringExpenseNet	6105000	USD
CY2015Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2254000	USD
CY2014Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2012000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2807000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6208000	USD
CY2015Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1030000	USD
CY2014Q3	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	1851000	USD
CY2015Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	17000	USD
CY2014Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	49000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1013000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1802000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-3820000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-8010000	USD
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.09
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	93943772	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	92971572	shares
CY2015Q3	plx	Revenues Other Than Company Share In Collaboration Agreement RevenuesOtherThanCompanyShareInCollaborationAgreement	4301000	USD
CY2014Q3	plx	Revenues Other Than Company Share In Collaboration Agreement RevenuesOtherThanCompanyShareInCollaborationAgreement	2396000	USD
CY2015Q3	plx	Company Share In Collaboration Agreement CompanyShareInCollaborationAgreement	1545000	USD
CY2014Q3	plx	Company Share In Collaboration Agreement CompanyShareInCollaborationAgreement	1311000	USD
CY2015Q3	us-gaap	Cost Of Revenue CostOfRevenue	2346000	USD
CY2014Q3	us-gaap	Cost Of Revenue CostOfRevenue	1798000	USD
CY2015Q3	us-gaap	Gross Profit GrossProfit	3500000	USD
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Entity Central Index Key EntityCentralIndexKey	0001006281
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	99800397	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18781572	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19797190	shares
CY2014Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	18661182	shares
CY2015Q3	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19820485	shares
CY2015Q3	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1502000	USD
CY2014Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	1616000	USD
CY2014Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	132000	USD
CY2015Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4837000	USD
CY2014Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	4919000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	1600000	USD
	us-gaap	Stock Issued During Period Shares Share Based Compensation Forfeited StockIssuedDuringPeriodSharesShareBasedCompensationForfeited	1834	shares
CY2015Q3	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	45500000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Trading Symbol TradingSymbol	PLX
	dei	Entity Registrant Name EntityRegistrantName	PROTALIX BIOTHERAPEUTICS, INC.
	dei	Document Type DocumentType	10-Q

Files In Submission

Name	View Source	Status
0001144204-15-063825-index-headers.html	Edgar Link	pending
0001144204-15-063825-index.html	Edgar Link	pending
0001144204-15-063825.txt	Edgar Link	pending
0001144204-15-063825-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
plx-20150930.xml	Edgar Link	completed
plx-20150930.xsd	Edgar Link	pending
plx-20150930_cal.xml	Edgar Link	unprocessable
plx-20150930_def.xml	Edgar Link	unprocessable
plx-20150930_lab.xml	Edgar Link	unprocessable
plx-20150930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v423042_10q.htm	Edgar Link	pending
v423042_ex10-1.htm	Edgar Link	pending
v423042_ex31-1.htm	Edgar Link	pending
v423042_ex31-2.htm	Edgar Link	pending
v423042_ex32-1.htm	Edgar Link	pending
v423042_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PLX
Protalix BioTherapeutics, Inc. Stock $plx

2015 Q4 Form 10-Q Financial Statement

#000114420415063825 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX Protalix BioTherapeutics, Inc. Stock $plx

2015 Q4 Form 10-Q Financial Statement

#000114420415063825 Filed on November 09, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PLX
Protalix BioTherapeutics, Inc. Stock $plx